EGFR and glioblastoma: When compared to EGFR and PTEN loss in GBM tumor samples, which again were used as positive and negative controls, the 15.4% frequency of ERBB4 copy number loss behaves qualitatively similarly to that of GBM tumor suppressor PTEN (Fig 3a).